Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection

被引：0

作者：

Glushko, Tetiana ^{[1
]}

Costello, James ^{[1
]}

Chima, Ranjit ^{[1
]}

McGettigan, Melissa ^{[1
]}

Kim, Richard ^{[1
]}

Jeong, Daniel ^{[1
]}

Qayyum, Aliya ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, 2902 USF Magnolia Dr, Tampa, FL 33612 USA

来源：

EUROPEAN JOURNAL OF RADIOLOGY | 2025年 / 187卷

关键词：

BILIARY-TRACT CANCER; MUTATIONS; CHEMOTHERAPY; ARID1A; MULTICENTER; EXPRESSION; PROGNOSIS; SURVIVAL; FEATURES; PATHWAY;

D O I：

10.1016/j.ejrad.2025.112056

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Cholangiocarcinoma is a highly lethal disease with a 5-year overall survival rate of 7-20%. A minority of patients present with resectable disease, and relapse rates remain high. Emerging data from next generation sequencing analysis have identified various actionable mutations which drive the different disease courses opening door to precision medicine and targeted therapies. This review focuses on the clinical significance of genetic alterations as well as the role of systemic therapies, immunotherapy and targeted therapies for intrahepatic cholangiocarcinoma.

引用

页数：28

共 50 条

[21] Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection
Jolissaint, Joshua S.
Soares, Kevin C.
Seier, Kenneth P.
Kundra, Ritika
Gonen, Mithat
Shin, Paul J.
Boerner, Thomas
Sigel, Carlie
Madupuri, Ramyasree
Vakiani, Efsevia
Cercek, Andrea
Harding, James J.
Kemeny, Nancy E.
Connell, Louise C.
Balachandran, Vinod P.
D'Angelica, Michael, I
Drebin, Jeffrey A.
Kingham, T. Peter
Wei, Alice C.
Jarnagin, William R.
CLINICAL CANCER RESEARCH, 2021, 27 (14) : 4101 - 4108
[22] New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma
Kawamura, Etsushi
Matsubara, Tsutomu
Kawada, Norifumi
CANCERS, 2023, 15 (15)
[23] Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions
Voss, Jesse S.
Holtegaard, Leonard M.
Kerr, Sarah E.
Fritcher, Emily G. Barr
Roberts, Lewis R.
Gores, Gregory J.
Zhang, Jun
Highsmith, W. Edward
Hailing, Kevin C.
Kipp, Benjamin R.
HUMAN PATHOLOGY, 2013, 44 (07) : 1216 - 1222
[24] Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis
Rahnemai-Azar, Amir A.
Weisbrod, Allison
Dillhoff, Mary
Schmidt, Carl
Pawlik, Timothy M.
SURGICAL ONCOLOGY-OXFORD, 2017, 26 (02): : 125 - 137
[25] Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma
Czauderna, Carolin
Kirstein, Martha M.
Tews, Hauke C.
Vogel, Arndt
Marquardt, Jens U.
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)
[26] Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy
Brown, Zachary J.
Hewitt, D. Brock
Pawlik, Timothy M.
FRONTIERS IN BIOSCIENCE-LANDMARK, 2022, 27 (03):
[27] Proton beam therapy for unresectable intrahepatic cholangiocarcinoma
Ohkawa, Ayako
Mizumoto, Masashi
Ishikawa, Hitoshi
Abei, Masato
Fukuda, Kuniaki
Hashimoto, Takayuki
Sakae, Takeji
Tsuboi, Koji
Okumura, Toshiyuki
Sakurai, Hideyuki
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (05) : 957 - 963
[28] Intrahepatic cholangiocarcinoma—diagnostic and therapy
Saborowski A.
Vogel A.
Der Gastroenterologe, 2018, 13 (5): : 366 - 371
[29] The role of ALPPS in intrahepatic cholangiocarcinoma
Bednarsch, Jan
Czigany, Zoltan
Lurje, Isabella
Strnad, Pavel
Bruners, Philipp
Ulmer, Tom Florian
den Dulk, Marcel
Lurje, Georg
Neumann, Ulf Peter
LANGENBECKS ARCHIVES OF SURGERY, 2019, 404 (07) : 885 - 894
[30] Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience
Wang, Longrong
Zhu, Hongxu
Zhao, Yiming
Pan, Qi
Mao, Anrong
Zhu, Weiping
Zhang, Ning
Lin, Zhenhai
Zhou, Jiamin
Wang, Yilin
Zhang, Yongfa
Wang, Miao
Feng, Yun
He, Xigan
Xu, Weiqi
Wang, Lu
JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)

← 1 2 3 4 5 →